Spyre Therapeutics, Inc. SYRE Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Spyre Therapeutics, Inc. (SYRE) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $1.06M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Spyre Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 556.5% year-over-year, from $161K to $1.06M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a 55.3% compound annual growth rate (CAGR), from $31K to $116K.